The fastest rising cause of cancer-related death in the United States, hepatocellular carcinoma (HCC) accounts for between 85-90% of primary liver cancers. Because the disease is frequently diagnosed when the cancer has advanced, liver cancers have one of the highest mortality rates with a 5-year survival rate of less than 15 percent.

With more than 780,000 new cases of primary liver cancer diagnosed worldwide each year, Surefire Medical is committed to further improving patient outcomes in solid tumors. High intratumoral pressure created by the tumor microenvironment limits the flow and accumulation of therapy in solid tumors. By creating a favorable pressure gradient, interventional medical devices employing Pressure-Enabled Delivery (PED) technology can increase drug concentration in the tumor—without increasing systemic toxicity. Therefore, the Surefire® Infusion System (SIS) HCC registry generates real-world clinical data that helps refine our understanding of which candidates are most likely to benefit from PED technology.

The SIS registry included 72 HCC patients treated with Surefire PED technology at 10 leading oncology centers in the United States. Based on interim data, HCC patients treated with Drug-Eluting Beads Transarterial Chemoembolization (DEB-TACE) using the SIS for delivery achieved high tumor response rates that are durable up to 6-months based on follow-up. The one-month, three-month and six-month Objective Response Rates (ORRs) were 75.3%, 75.1% and 82.2%, respectively. High ORRs were observed in tumors greater than 3 cm at one, three and six months.  

Interim results confirm that physicians can effectively use the SIS in DEB-TACE across a wide range of HCC patients to achieve high response rates—without compromising patient safety.

Read the press release for more information on the clinical data.